Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:
“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.
Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.
If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.
600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.
This is especially important in ITP, where many patients still have limited durable responses to existing therapies.
By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”
Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 3, 2026, 16:01Your First Steps After an ITP Diagnosis – ITP Support Association
-
Aug 3, 2026, 15:33Christina Crossette-Thambiah: Scientific Excellence and Mentorship at ISTH 2026
-
Aug 3, 2026, 15:22Connie Montgomery: Why Global Support is Essential for the HFA Black Voices Initiative
-
Aug 3, 2026, 15:18Ifeanyichukwu Ifechidere: The DOAC Monitoring Masterclass
-
Aug 3, 2026, 15:02David McIntosh: UK Plasma Action – a Founder’s Reflections
-
Aug 3, 2026, 14:49Ney Carter Borges: Targeting the Gut Microbiome to Prevent Atrial Fibrillation
-
Aug 3, 2026, 13:42Immune Thrombocytopenia: Moving Beyond Platelet Counts Toward Durable Remission
-
Aug 3, 2026, 13:28Aboo Shama Khan: Pulmonary Embolism – A Medical Emergency Every Nurse Must Recognize
-
Aug 3, 2026, 13:08Ashwin Patel: Evaluating Red Cell Function Post-Treatment in SCD Patients